Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← MIB-626
reduces riskIncreased
risk →
reduces riskIncreased
risk →
MIB-626 for COVID-19
1
study with
39
patients
Serious outcome risk
No significant improvements are seen in meta-analysis to date.
COVID-19 MIB-626 studies · November 2026
|
Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← MIB-626
reduces riskIncreased risk → |
Jun 18 2025 |
et al., FASEB BioAdvances, doi:10.1096/fba.2025-00014 | Oral MIB‐626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID‐19 and Acute Kidney Injury: A Randomized Controlled Trial |
| 156% higher mortality (p=1) and 18% improved recovery (p=0.71). RCT 42 hospitalized patients with COVID-19 and acute kidney injury (AKI) showing no clinical benefit with MIB-626 (β-nicotinamide mononucleotide) treatment. The study found that 1.0g of MIB-626 twice daily safely and significantly raised .. | ||
